A Phase 4 interventional study of Oral rehydration fluid and Isotonic hydration fluid and recombinant human hyaluronidase in Dehydration, sponsored by Baxter Healthcare Corporation. Withdrawn. Open to participants aged 2 Months to 2 Years. Per ClinicalTrials.gov, last updated 2017-05-08.
Sponsored by Baxter Healthcare Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose is to evaluate the safety and efficacy as well as the time and resources needed in the ED setting to achieve rehydration in young pediatric subjects with mild to moderate dehydration using hylenex-facilitated SC rehydration versus oral rehydration therapy.
201 studies on the registry are indexed under Dehydration; 28 are open to participants now.
Browse Dehydration studies →Baxter Healthcare Corporation is the lead sponsor of 80 studies on the registry; 1 is open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Oral rehydration fluid
Drug: Isotonic hydration fluid and recombinant human hyaluronidase
Oral electrolyte solution or other clinically acceptable oral rehydration fluid, 5 to 10 mL of offered with encouragement every 5 to 10 minutes
Also known as: oral rehydration salts
Drug page: Hyaluronidase (human recombinant)
Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
Also known as: hyelenx, rHuPH20, Lactated Ringer's solution, normal saline solution, 0.9% sodium chloride solution
Total resource utilization in the ED
Time frame: 2 to 8 hours
Rate of successful rehydration in the ED
Clinical judgement of adequate hydration, and either: 1) stable or increased body weight or 2) urine production
Time frame: 2 to 8 hours
Time to ED discharge
Time frame: 2 to 8 hours
Amount of rehydration fluid administered
Time frame: 2 to 8 hours
Global satisfaction and ease-of-use assessments by healthcare provider(s) and parent/caregiver
Time frame: 2 to 8 hours
Occurrence of infusion site pain or other local reactions
Time frame: 2 to 8 hours
Occurrence of other adverse events
Time frame: 7 days
Vital signs
Blood pressure, heart rate, respiratory rate, temperature
Time frame: 2 to 8 hours
No study locations are listed for this record.
Start is estimated for May 2010; primary completion for May 2010, 0 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronidase (human recombinant)
Baxter Healthcare Corporation →